On Thursday, Rosenblatt Securities reaffirmed its positive stance on IMAX Corporation (NYSE: NYSE:IMAX), maintaining a Buy rating and a price target of $28.00. The company, currently valued at $1.19 billion, has demonstrated strong market performance with a 61.1% return over the past year, according to InvestingPro data.
The firm’s analysts made adjustments to their estimates in light of the recently released Q4 Gross Box Office results from IMAX. The figures fell short of expectations, impacted by the weaker-than-anticipated performance of ’Joker 2’ and a shift in the Chinese market towards comedies over the action films that typically fare better in IMAX formats.
Despite the Q4 shortfall, Rosenblatt’s analysts believe IMAX is well-positioned for future success. They highlighted the strong lineup of films slated for 2025, including a record number of titles filmed specifically for IMAX and several eagerly awaited blockbuster films. These factors are expected to support the company’s performance moving forward. InvestingPro analysis reveals the company maintains a healthy financial position with a current ratio of 3.31, indicating strong liquidity to support its expansion plans.
The analysts noted that IMAX shares are currently trading at an attractive valuation, specifically 8.9 times the enterprise value to adjusted EBITDA for 2025. While InvestingPro’s Fair Value analysis suggests the stock is currently fairly valued, analyst price targets range from $16 to $33, with a strong consensus recommendation of 1.64 (where 1 is Strong Buy and 5 is Strong Sell).
This valuation, coupled with the promising film slate, underpins their recommendation to buy IMAX shares. They anticipate that the robust lineup for 2025 could lead to upward revisions in financial projections and an expansion of the company’s trading multiple.
IMAX is scheduled to report its full-year results on March 4, 2025, and these results will provide further insight into the company’s financial health and its outlook for the coming year. With a gross profit margin of 54.5% in the last twelve months, investors will be watching closely to see if the company can maintain its strong profitability metrics. The analysts’ current estimates have been adjusted to reflect the Q4 Gross Box Office data, which serves as a precursor to the comprehensive annual report.
In other recent news, IMAX Corporation has shown impressive financial performance, exceeding expectations in its Q3 2024 earnings call. The company reported an adjusted EBITDA of $39 million, a 42% margin, and earnings per share (EPS) of $0.35, surpassing forecasts by over 50%. The Q3 revenue was reported at $91.5 million, primarily driven by major titles and content solutions.
Benchmark analysts have maintained their Buy rating for IMAX, with a price target of $30.00 based on the company’s robust growth outlook for 2025. This optimism is rooted in IMAX’s strategy to focus on localized content, including seven filmed-for-IMAX Chinese titles expected to meet premium demand and grow its market share in the region.
In addition, B. Riley increased its shares target for IMAX from $30.00 to $33.00, maintaining a Buy rating. This decision was based on a recent investor call with IMAX’s top management, which provided deeper insights into the company’s strategic position within the film industry. The company anticipates a global box office exceeding $1.2 billion in 2025, supported by a strong film slate.
IMAX’s financial health appears robust, with $105 million in cash, $280 million in debt, and liquidity exceeding $410 million. The company has also seen a significant increase in system installations, expecting to end the year within the range of 130-150.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.